Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2 clinical trials
Cemiplimab-rwlc for Unresectable Locally Recurrent and/or Metastatic CSCC

The purpose of this research study is to determine how people with weakened immune systems and unresectable (cannot be removed by surgery) locally recurrent and/or metastatic cutaneous squamous cell carcinoma (CSCC) respond to study treatment with Cemiplimab. Cemiplimab is approved for sale in United States by the U.S.

cemiplimab
metastasis
acquired immunodeficiency syndrome (aids)
lymphoma
cancer
  • 0 views
  • 19 Feb, 2024
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow …

monoclonal antibodies
follicle stimulating hormone
oophorectomy
hypothyroidism
carcinoma
  • 0 views
  • 19 Feb, 2024